Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

Scandinavian Journal of Gastroenterology

Volumn 52, Issue 6-7, 2017, Pages 722-729

  Eriksson, Carl ^a   Marsal, Jan ^b,c   Bergemalm, Daniel ^a   Vigren, Lina ^d   Björk, Jan ^e   Eberhardson, Michael ^e   Karling, Pontus ^f   Söderman, Charlotte ^g   Myrelid, Pär ^h   Cao, Yang ^i,j   Sjöberg, Daniel ^k   Thörn, Mari ^k   Karlén, Per ^l   Hertervig, Erik ^c   Strid, Hans ^m   Ludvigsson, Jonas F ^j,n   Almer, Sven ^e   Halfvarson, Jonas ^a   Cejvan, Kenan ^o   Delin, Jenny ^p   Eriksson, Anders ^q   Grip, Olof ^c   Hjortswang, Henrik ^h   Höög, Charlotte ^e   Jäghult, Susanna ^l   Mavroudis, Georgios ^q   Stjernman, Henrik ^r   more..

^a Örebro University   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Ystad Hospital   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g ST GÖRAN S HOSPITAL   (Sweden)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ ÖREBRO UNIVERSITY   (Sweden)

^j KAROLINSKA INSTITUTE   (Sweden)

^k UPPSALA UNIVERSITY   (Sweden)

^l DANDERYD HOSPITAL   (Sweden)

^m Sodra Alvsborgs Sjukhus   (Sweden)

ⁿ ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^o Västerås Central Hospital   (Sweden)

^p ERSTA HOSPITAL   (Sweden)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^r RYHOV COUNTY HOSPITAL   (Sweden)

more..

Author keywords

clinical practice; Crohn s disease; inflammatory bowel disease; ulcerative colitis; Vedolizumab

Indexed keywords

CALGRANULIN; VEDOLIZUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COHORT ANALYSIS; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; SWEDEN; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SWEDEN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85018512957     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2017.1304987     Document Type: Article

References (33)

1. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis:the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–623.
2. Andersen NN, Jess T., Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20:16014–16019.
3. Khanna D, McMahon M, Furst DE., Anti-tumor necrosis factor alpha therapy and heart failure:what have we learned and where do we go from here? Arthritis Rheum. 2004;50:1040–1050.
4. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490–1497.
5. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
6. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
7. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618–627.e3.
8. Emilsson L, Lindahl B, Koster M, et al. Review of 103 Swedish Healthcare Quality Registries. J Intern Med. 2015;277:94–136.
9. Swedish Inflammatory Bowel Disease Registry. SWIBREG 2016 [Internet] [cited 2007] Jan 20. Available from:http://www.swibreg.se.
10. Ludvigsson JF, Myrelid P., [SWIBREG–a new version of national IBD registry]. Lakartidningen. 2009;106:3014–3015.
11. Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. ECCOJC. 2016;10:402–409.
12. Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;11:1593–1601.
13. Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice–a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090–1102.
14. Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients:a multicenter cohort. Inflamm Bowel Dis. 2015;21:2879–2885.
15. Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease–a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199–1212.
16. Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2121–2126.
17. Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe crohn’s disease:results from the US VICTORY Consortium. Am J Gastroenterol. 2016;111:1147–1155.
18. Bennebroek Evertsz F, Hoeks CC, Nieuwkerk PT, et al. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn’s disease activity. J Clin Gastroenterol. 2013;47:850–856.
19. Harvey RF, Bradshaw JM., A simple index of Crohn’s disease activity. Lancet. 1980;1:514.
20. af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47:528–537.
21. Bennebroek Evertsz F, Nieuwkerk PT, Stokkers PC, et al. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission:a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohn’s Colitis. 2013;7:890–900.
22. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
23. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.
24. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.
25. Hornung RW, Reed LD., Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg. 1990;5:46–51.
26. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number:possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659–667.
27. Loikas D, Wettermark B, von Euler M, et al. Differences in drug utilisation between men and women:a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open. 2013;3. doi:http://dx.doi.org/10.1136/bmjopen-2012-002378.
28. Jurgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–427.
29. Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease:a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576.
30. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
31. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.
32. Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244–252.
33. Souto A, Maneiro JR, Gomez-Reino JJ., Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis:a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523–534.